Inmunología Beneficios y ventajas de la terapia antiretroviral altamente activa (HAART). Otras alternativas
Referencias
Alfonzo
M, Blanc D, Troadec C, Eliaszewicz M, Gonzalez G, Scott-Algara D.(2003)
Partial restoration of cytokine profile despite reconstitution of cytomegalovirus-specific
cell-mediated immunity in human immunodeficiency virus-infected patients
during highly active antiretroviral treatment. Scand J Immunol. Apr;57(4):375-83.
Altfeld,
M., and Rosenberg, E. S. (2000). The
role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to
HIV-1. Curr Opin Immunol 12(4), 375-80
Andersson,
J., T. E. Fehniger, B. K. Patterson, J. Pottage, M. Agnoli, P. Jones, H.
Behbahani, and A. Landay (1998). Early reduction of immune activation
in lymphoid tissue following highly active HIV therapy Aids. 12:F123-9.
Autran,
B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama,
C., Debre, P., and Leibowitch, J. (1997). Positive effects of combined
antiretroviral therapy on CD4+ T cell homeostasis and function in advanced
HIV disease. Science 277(5322), 112-6.
Badley,
A. D., Pilon, A. A., Landay, A., and Lynch, D. H. (2000). Mechanisms
of HIV-associated lymphocyte apoptosis. Blood 96(9), 2951-64.
Barre-Sinoussi,
F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet,
C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux , C.; Rozenbaum, W.; Montagnier,
L. (1983). Isolation of a T-lymphotropic
retrovirus from a patient at risk for adquired immune deficiency syndrome
(AIDS). Science. 220 : 868-871
Berger,
E.A.; Murphy, P.M.; Farber, J.M. (1999).
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism,
and disease. Annu Rev Immunol. 17:657-700.
Bonhoeffer,
S.;Rembiszewski, M.; Ortiz, G. M. and Nixon, D. F. (2000). Risks
and benefits of structured antiretroviral drug therapy interruptions in
HIV-1 infection. Aids 14(15), 2313-22.
Bucy,
R. P., R. D. Hockett, C. A. Derdeyn, M. S. Saag, K. Squires, M. Sillers,
R. T. Mitsuyasu, and J. M. Kilby (1999). Initial increase in blood
CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution
from lymphoid tissues J Clin Invest. 103:1391-8
Cameron,
P. U., Freudenthal, P. S., Barker, J. M., Gezelter, S., Inaba, K., and Steiman,
R. M. (1992). Dendritic cells exposed
to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection
to CD4+ T cells. Science 257(5068), 383-7.
Cameron,
P. U., Lowe, M. G., Sotzik, F., Coughlan, A. F., Crowe, S. M., and Shortman,
K. (1996). the interaction of macrophage and non-macrophage tropic
isolates of hiv- 1 with thymic and tonsillar dendritic cells in vitro. J
Exp Med 183(4), 1851-6.
Carcelain,
G., C. Blanc, J. Leibowitch, P. Mariot, D. Mathez, V. Schneider, A. G. Saimot,
F. Damond, F. Simon, P. Debre, B. Autran, and P. M. Girard (1999).
T cell changes after combined nucleoside analogue therapy in HIV primary
infection Aids. 13:1077-81.
Carpenter,
C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein,
J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson,
S. Vella, P. G. Yeni, and P. A. Volberding (1998). Antiretroviral
therapy for HIV infection in 1998: updated recommendations of the International
AIDS Society-USA Panel Jama. 280:78-86.
Clerici,
M., Stocks, N. I., Zajac, R. A., Boswell, R. N., Lucey, D. R., Via, C. S.,
and Shearer, G. M. (1989). Detection of three distinct patterns
of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive
patients. Independence of CD4+ cell numbers and clinical staging. J Clin
Invest 84(6), 1892-9.
Coffin,
J.; Haase, A.; Levy, J.A.; Montagnier, L.; Oroszlan, S.; Teich, N.; Temin,
H.; Toyoshima, K.; Varmus, H.; Vogt P. and Weiss, R. Human immunodeficiency
viruses. (1986). Science. 232(4751):697.
Dalgleish,
A.G.; Beverley, P.C.; Clapman, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss,
R.A. (1984). The CD4 (T4) antigen is an essential component of
the receptor for the AIDS retrovirus. Nature. 312: 763-767.
Dimitrov
DS. (1997). How do viruses enter cells? The HIV coreceptors teach
us a lesson of complexity. Cell. 91(6):721-30.
Dybul,
M., Chun, T. W., Yoder, C., Hidalgo, B., Belson, M., Hertogs, K., Larder,
B., Dewar, R. L., Fox, C. H., Hallahan, C. W., Justement, J. S., Migueles,
S. A., Metcalf, J. A., Davey, R. T., Daucher, M., Pandya, P., Baseler, M.,
Ward, D. J., and Fauci, A. S. (2001).
Short-cycle structured intermittent treatment of chronic HIV infection with
highly active antiretroviral therapy: effects on virologic, immunologic,
and toxicity parameters. Proc Natl Acad Sci U S A 98(26), 15161-6
Fauci,
A.S. (1996). Host factors and the pathogenesis of HIV-induced disease.
Nature. 384(6609):529-534.
Gallo,
R.C. ; Sarin, P.S. ; Gelmann, E.P. ; Robert-Guroff, M. ; Richardson, E.;
Kalyanaraman, V.S.; Mann, D.; Sidhu, G.D.; Sthal, R.E.; Zoila-Pazner, S.;
Leibowitch, J. and Popovic, M. (1983). Isolation of human T-cell
leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 220:
865-867.
Graziosi,
C.; Soudeyns, H.; Rizzardi, G.P.; Bart, P.A.; Chapuis, A.; Pantaleo, G.
(1998). Immunopathogenesis of HIV infection. AIDS Res. Hum. Retroviruses.
14:S135-S142.
Gulick,
R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D.
D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A.
Chodakewitz (1997). Treatment with indinavir, zidovudine, and lamivudine
in adults with human immunodeficiency virus infection and prior antiretroviral
therapy N Engl J Med. 337:734-9.
Hammer,
S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier,
J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A.
Chodakewitz, and M. A. Fischl (1997). A controlled trial of two
nucleoside analogues plus indinavir in persons with human immunodeficiency
virus infection and CD4 cell counts of 200 per cubic millimeter or less.
AIDS Clinical Trials Group 320 Study Team N Engl J Med. 337:725-33
Hellerstein,
M. K., and McCune, J. M. (1997). T cell turnover in HIV-1 disease.
Immunity 7(5), 583-9.
Ho,
D.D.; Neumann, A.U.; Perelson, A.S.; Chen, W.; Leonard, J.M.; Markowitz,
M.(1995). Rapid turnover of plasma virions and CD4 lymphocytes
in HIV-1 infection. Nature. 373(6510):123-6
Hogg,
R. S., M. V. O'Shaughnessy, N. Gataric, B. Yip, K. Craib, M. T. Schechter,
and J. S. Montaner (1997). Decline in deaths from AIDS due to new
antiretrovirals Lancet. 349:1294.
International
Labour Organization. 2000. HIV/AIDS: a threat to decent work, productivity
and development. International Labour Organization, Geneva, Switzerland.
Kaufmann,
D., G. Pantaleo, P. Sudre, and A. Telenti
(1998). CD4-cell count in HIV-1-infected individuals remaining viraemic
with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
Lancet. 351:723-4.
Kilby,
J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee,
L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson,
M. A. Nowak, G. M. Shaw, and M. S. Saag
(1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide
inhibitor of gp41-mediated virus entry Nat Med. 4:1302-7.
Klatzmann,
D.; Barre-Sinoussi, F.; Nugeyre, MT.; Danquet, C.; Vilmer, E.; Griscelli,
C.; Brun-Veziret, F.; Rouzioux, C.; Gluckman, J.C. and Chermann, J.C. (1984a).
Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer
T lymphocytes. Science. 225(4657):59-63.
Klatzmann,
D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman,
J.C. and Montagnier, L. (1984b). T-lymphocyte T4 molecule behaves
as the receptor for human retrovirus LAV. Nature. 312(5996):767-8.
Komanduri,
K. V., Feinberg, J., Hutchins, R. K., Frame, R. D., Schmidt, D. K., Viswanathan,
M. N., Lalezari, J. P., and McCune, J. M. (2001). Loss of cytomegalovirus-specific
CD4+ T cell responses in human immunodeficiency virus type 1-infected patients
with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 183(8),
1285-9.
Lederman,
M. M. 2001. Immune restoration and
CD4+ T-cell function with antiretroviral therapies Aids. 15 Suppl 2:S11-5.
Lisziewicz,
J., Rosenberg, E., Lieberman, J., Jessen, H., Lopalco, L., Siliciano, R.,
Walker, B., and Lori, F. (1999). Control of HIV despite the discontinuation
of antiretroviral therapy. N Engl J Med 340(21), 1683-4.
Marriott,
D. & McMurchie, M. (1996). Managing HIV. Part 2: Phases of
disease. 2.4 HIV and advanced immune deficiency. Med. J. Aust. 164(2): 111-2
Miedema,
F., Petit, A. J., Terpstra, F. G., Schattenkerk, J. K., de Wolf, F., Al,
B. J., Roos, M., Lange, J. M., Danner, S. A., Goudsmit, J., and et al.
(1988). Immunological abnormalities in human immunodeficiency virus (HIV)-
infected asymptomatic homosexual men. HIV affects the immune system before
CD4+ T helper cell depletion occurs. J Clin Invest 82(6), 1908-14.
Miller,
V., Sabin, C., Hertogs, K., Bloor, S., Martinez-Picado, J., D'Aquila, R.,
Larder, B., Lutz, T., Gute, P., Weidmann, E., Rabenau, H., Phillips, A.,
and Staszewski, S. (2000). Virological and immunological effects
of treatment interruptions in HIV- 1 infected patients with treatment failure.
Aids 14(18), 2857-67.
Neumann,
A. U., Tubiana, R., Calvez, V., Robert, C., Li, T. S., Agut, H., Autran,
B., and Katlama, C. (1999). HIV-1 rebound during interruption of
highly active antiretroviral therapy has no deleterious effect on reinitiated
treatment. Comet Study Group. Aids 13(6), 677-83.
NIH.
Plan del año fiscal 2003 de los NIH para investigaciones relacionadas
con el VIH. (2003). 1-40
Oberlin,
E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J.L.; Arenzana-Seisdedos,
F.; Schwartz, O.; Heard, J.M.; Clark-Lewis, I.; Legler, D.F.; Loetscher,
M.; Baggiolini, M. and Pantaleo, G.; Fauci, A.S. (1996). Immunopathogenesis
of HIV infection. Annu. Rev. Microbiol. 50:825-854.
Ortiz,
G. M., Nixon, D. F., Trkola, A., Binley, J., Jin, X., Bonhoeffer, S., Kuebler,
P. J., Donahoe, S. M., Demoitie, M. A., Kakimoto, W. M., Ketas, T., Clas,
B., Heymann, J. J., Zhang, L., Cao, Y., Hurley, A., Moore, J. P., Ho, D.
D., and Markowitz, M. (1999). HIV-1-specific
immune responses in subjects who temporarily contain virus replication after
discontinuation of highly active antiretroviral therapy. J Clin Invest 104(6),
R13-8.
Pakker,
N. G., D. W. Notermans, R. J. de Boer, M. T. Roos, F. de Wolf, A. Hill,
J. M. Leonard, S. A. Danner, F. Miedema, and P. T. Schellekens
(1998). Biphasic kinetics of peripheral blood T cells after triple combination
therapy in HIV-1 infection: a composite of redistribution and proliferation
Nat Med. 4:208-14.
Palella,
F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G.
A. Satten, D. J. Aschman, and S. D. Holmberg (1998). Declining
morbidity and mortality among patients with advanced human immunodeficiency
virus infection. HIV Outpatient Study Investigators N Engl J Med. 338:853-60.
Pantaleo,
G., and Fauci, A. S. (1996). Immunopathogenesis of HIV infection.
Annu Rev Microbiol 50, 825-54.
Pérez-Casas,
C.; Verman, D.; Chirac, P.; Kasper, T.; Pécoul, B.; Vicenzi, I.,
Von Schoen, T. Proyecto de acceso a medicamentos esenciales. Médicos
sin fronteras. 2000.
Pérez-Casas,
C.; Verman, D.; Chirac, P.; Kasper, T.; Pécoul, B.; Vicenzi, I., Von
Schoen, T(2000). Proyecto de acceso a medicamentos esenciales. Médicos
sin fronteras.
Plana,
M., Garcia, F., Gallart, T., Miro, J. M., and Gatell, J. M. (1998).
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of
highly active antiretroviral treatment in early HIV-1 disease. Immunology
Study Group of Spanish EARTH-1 Study. Lancet 352(9135), 1194-5.
PNUD.
Informe sobre el Desarrollo Humano en el año 2000: Derechos Humanos
y Desarrollo Humano. (2000).
Richman,
D. D. (2001). HIV Chemotherapy. Nature. 410 (6831): 995-2001.
Rinaldo, C. R.,
Jr., Liebmann, J. M., Huang, X. L., Fan, Z., Al-Shboul, Q., McMahon, D. K.,
Day, R. D., Riddler, S. A., and Mellors, J. W. (1999). Prolonged
suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons
with advanced disease results in enhancement of CD4 T cell reactivity to microbial
antigens but not to HIV-1 antigens. J Infect Dis 179(2), 329-36.
Rizzardi, G.
P., G. Tambussi, P. A. Bart, A. G. Chapuis, A. Lazzarin, and G. Pantaleo 2000.
Virological and immunological responses to HAART in asymptomatic therapy-naive
HIV-1-infected subjects according to CD4 cell count Aids. 14:2257-63.
Rosok, B. I.,
Bostad, L., Voltersvik, P., Bjerknes, R., Olofsson, J., Asjo, B., and Brinchmann,
J. E. (1996). Reduced CD4 cell counts in blood do not reflect CD4
cell depletion in tonsillar tissue in asymptomatic HIV-1 infection. Aids 10(10),
F35-8.
Rosenberg, E.
S., M. Altfeld, S. H. Poon, M. N. Phillips, B. M. Wilkes, R. L. Eldridge,
G. K. Robbins, R. T. D'Aquila, P. J. Goulder, and B. D. Walker 2000.
Immune control of HIV-1 after early treatment of acute infection Nature. 407:523-6.
Rosenberg, E.
S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams,
S. A., and Walker, B. D. (1997). Vigorous HIV-1-specific CD4+ T cell
responses associated with control of viremia. Science 278(5342), 1447-50.
Sachsenberg,
N., A. S. Perelson, S. Yerly, G. A. Schockmel, D. Leduc, B. Hirschel, and
L. Perrin 1998. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1
infection as measured by Ki-67 antigen J Exp Med. 187:1295-303.
Sam, B. ONUSIDA.,
citado en OMS-Health and Technology Pharmaceuticals, Estrategia Revisada de
Medicamentos, 2001.
Sloand, E. M.,
P. N. Kumar, S. Kim, A. Chaudhuri, F. F. Weichold, and N. S. Young
1999. Human immunodeficiency virus type 1 protease inhibitor modulates activation
of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis
in vitro and in vivo Blood. 94:1021-7.
Spira, A. I.,
Marx, P. A., Patterson, B. K., Mahoney, J., Koup, R. A., Wolinsky, S. M.,
and Ho, D. D. (1996). Cellular targets of infection and route of
viral dissemination after an intravaginal inoculation of simian immunodeficiency
virus into rhesus macaques. J Exp Med 183(1), 215-25.
Staszewski, S.,
V. Miller, C. Sabin, C. Schlecht, P. Gute, S. Stamm, T. Leder, A. Berger,
E. Weidemann, A. Hill, and A. Phillips 1999. Determinants of sustainable
CD4 lymphocyte count increases in response to antiretroviral therapy Aids.
13:951-6
Stein, D.S.;
Korvick, J.A.; Vermund, S.H. (1992). CD4+ lymphocyte cell enumeration
for prediction of clinical course of human immunodeficiency virus disease:
a review. J. Infect. Dis. 165(2):352-363.
Tenner-Racz,
K., H. J. Stellbrink, J. van Lunzen, C. Schneider, J. P. Jacobs, B. Raschdorff,
G. Grosschupff, R. M. Steinman, and P. Racz 1998. The unenlarged
lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell
counts are sites for virus replication and CD4 T cell proliferation. The impact
of highly active antiretroviral therapy J Exp Med. 187:949-59.
UNAIDS
(1999). AIDS epidemic update: December 1999. UNAIDS, Geneva, Switzerland.
UNAIDS.
(2000). Report on the global HIV-AIDS epidemic
UNAIDS.
(2003). Report on the global HIV-AIDS epidemic
Urbaneja, María.
Ponencia ante el 26° período extraordinario de sesiones de la Asamblea
General de las Naciones Unidas dedicado a la revisión del VIH/SIDA
en todos sus aspectos. (2001). New York, E.E.U.U.
USAID.
(1999a). HIV/AIDS briefs: the economic impact of AIDS. USAID, Washington,
D.C.
USAID.
(1999b). The economic impact of AIDS in Africa. USAID, Washington, D.C.
Youle, M.
(2000). Is interruption of HIV therapy always harmful? J Antimicrob Chemother
45(2), 137-8.
Wolthers, K.
C., Schuitemaker, H., and Miedema, F. (1998). Rapid CD4+ T-cell turnover
in HIV-1 infection: a paradigm revisited. Immunol Today 19(1), 44-8.
World Bank. (1993).
World development report 1993: investing in health. Oxford Press, New York,
N.Y.
World Bank.
(1997). Confronting AIDS: public priorites in a global epidemic. World Bank,
New York, N.Y.
World Bank.
(1993). Investing in HIV/AIDS. World Bank, Washington, D.C.
Vigh, L.; Maresca,
B.; Harwood, J. L. (1998) Does the membrane's physical state control
the expression of heat shock and other genes? Trends Biochem Sci. 23(10),
369-74
Vigouroux, C.;
Gharakhanian, S.; Salhi, Y.; Nguyen, T. H.; Chevenne, D.; Capeau, J. and Rozenbaum,
W. (1999). Diabetes, insulin resistance and dyslipidaemia in lipodystrophic
HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes
Metab 25 (3), 225-232.
Zhang,
Z. Q., Notermans, D. W., Sedgewick, G., Cavert, W., Wietgrefe, S., Zupancic,
M., Gebhard, K., Henry, K., Boies, L., Chen, Z., Jenkins, M., Mills, R.,
McDade, H., Goodwin, C., Schuwirth, C. M., Danner, S. A., and Haase, A.
T. (1998). Kinetics of CD4+ T cell repopulation of lymphoid tissues
after treatment of HIV-1 infection. Proc Natl Acad Sci U S A 95(3), 1154-9.
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit